Study to Evaluate if Inhaled Nitric Oxide Improves Liver Function After Transplantation

Model scores of the 29,894 trials active now.

Model score 26% for any early termination, 14% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 15% of the time (107 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2012-10-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: transplantationinjuryplacebo controlledof ageinhaled
  Phrases that lowered it: patientseffect ofprovidedstudiessetting
• Sponsor's past termination rate: 12.2% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2/3 (raises risk) · Design
• Blinding: quadruple (lowers risk) · Design
• Minimum age: 19 (lowers risk) · Who can join
• Drug's FAERS reports marked serious: 96.4% (raises risk) · Drug's FDA history
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Drug's FAERS reports with a death: 28.9% (raises risk) · Drug's FDA history
• Design: parallel (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 36 (lowers risk) · Sponsor's track record
• Has a data monitoring committee: No (lowers risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Disease area, cardiovascular: Yes (raises risk) · Disease area
• Maximum age: 80 (lowers risk) · Who can join
• Number of arms: 2 (raises risk) · Design
• Responsible party: principal investigator (lowers risk) · Design
• Sponsor's past trials: 49 (raises risk) · Sponsor's track record
• Keywords listed: 5 (lowers risk) · Design
• Collaborators: 2 (lowers risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Trial of Inhaled Nitric Oxide (iNO) on Ischemia / Reperfusion Injury During Orthotopic Liver Transplantation With Marginal Grafts NCT01172691 · started 2010 · scored riskier than 55% of active trials completed
• Sodium Nitrite in Lung Transplant Patients to Minimize the Risk of Pulmonary Graft Dysfunction NCT01715883 · started 2011 · scored riskier than 66% of active trials terminated
• Randomized Trial of Inhaled Nitric Oxide to Augment Tissue Perfusion in Sepsis NCT00608322 · started 2009 · scored riskier than 93% of active trials completed
• Nitric Oxide-mediated Cardioprotection During Cardiac Surgery With Cardiopulmonary Bypass NCT03500783 · started 2015 · scored riskier than 54% of active trials completed
• Nitric Oxide Administration During Pediatric Cardiopulmonary Bypass Surgery to Prevent Platelet Activation NCT03455218 · started 2018 · scored riskier than 64% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.